Enzalutamide Before Surgery in Treating Patients With Kidney Cancer

Status Terminated

Clinical Trial Summary

This pilot phase 0 trial studies how well enzalutamide works before surgery in treating patients with kidney cancer. Androgens are a type of hormone produced by the body that may cause kidney tumors to grow. Anti-hormone therapy, such as enzalutamide, may lessen the amount of androgens produced by the body and keep kidney tumors from growing.

Clinical Trial Description

PRIMARY OBJECTIVES: I. To investigate the effects of neoadjuvant enzalutamide on clear cell renal cell carcinoma (ccRCC). OUTLINE: Patients receive enzalutamide orally (PO) daily for 90 days in the absence of disease progression or unacceptable toxicity. Patients then undergo partial or radical nephrectomy. After completion of study treatment, patients are followed up every 3 months. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02885649
Study type	Interventional
Source	Rutgers, The State University of New Jersey
Contact
Status	Terminated
Phase	Early Phase 1
Start date	December 5, 2017
Completion date	March 2, 2020

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03163667` - CB-839 With Everolimus vs. Placebo With Everolimus in Participants With Renal Cell Carcinoma (RCC)	Phase 2
Withdrawn	`NCT02307474` - A Pilot Study of SBRT With Adjuvant Pazopanib for Renal Cell Cancer	N/A
Terminated	`NCT02628535` - Safety Study of MGD009 in B7-H3-expressing Tumors	Phase 1
Completed	`NCT00101114` - Sorafenib and Interferon Alfa in Treating Patients With Metastatic or Unresectable Kidney Cancer	Phase 2
Completed	`NCT00078858` - Mycophenolate Mofetil and Cyclosporine in Reducing Graft-Versus-Host Disease in Patients With Hematologic Malignancies or Metastatic Kidney Cancer Undergoing Donor Stem Cell Transplant	Phase 1/Phase 2
Recruiting	`NCT05363631` - Seleno-L Methionine (SLM)-Axitinib-Pembrolizumab	Phase 1/Phase 2
Terminated	`NCT01198158` - Everolimus With or Without Bevacizumab in Treating Patients With Advanced Kidney Cancer That Progressed After First-Line Therapy	Phase 3
Completed	`NCT00378703` - Bevacizumab, Sorafenib Tosylate, and Temsirolimus in Treating Patients With Metastatic Kidney Cancer	Phase 2
Recruiting	`NCT06138496` - Cadonilimab Combination With Lenvatinib as Neoadjuvant Therapy for ccRCC	Phase 2
Recruiting	`NCT06088134` - Contrast-enhanced CT-based Deep Learning Model for Preoperative Prediction of Disease-free Survival (DFS) in Localized Clear Cell Renal Cell Carcinoma (ccRCC)
Recruiting	`NCT06049576` - Nivolumab and Ipilimumab With and Without Camu Camu for the Treatment of Patients With Metastatic Renal Cell Carcinoma	Phase 1
Active, not recruiting	`NCT01038778` - Entinostat in Combination With Aldesleukin in Treating Patients With Metastatic Kidney Cancer	Phase 1/Phase 2
Recruiting	`NCT05536141` - A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other Solid Tumors	Phase 1
Recruiting	`NCT05119335` - A Study of NKT2152, a HIF2α Inhibitor, in Patients With Advanced Clear Cell Renal Cell Carcinoma	Phase 1/Phase 2
Completed	`NCT01243359` - Sunitinib Malate and Bevacizumab in Treating Patients With Kidney Cancer or Advanced Solid Malignancies	Phase 1
Terminated	`NCT00098618` - Sorafenib and Interferon Alfa in Treating Patients With Locally Advanced or Metastatic Kidney Cancer	Phase 2
Recruiting	`NCT05620134` - Study of JK08 in Patients With Unresectable Locally Advanced or Metastatic Cancer	Phase 1/Phase 2
Recruiting	`NCT06052852` - Study of BDC-3042 as Single Agent and in Combination With Pembrolizumab in Patients With Advanced Malignancies	Phase 1/Phase 2
Completed	`NCT03680521` - Neoadjuvant Sitravatinib in Combination With Nivolumab in Patients With Clear Cell Renal Cell Carcinoma	Phase 2
Recruiting	`NCT06195150` - Overtaking Intra and Inter Tumoral Heterogeneity In Von Hippel-Lindau Related Renal Cancer